-transparent.png){kind=logo}
To assess the histological grade in benign and malignant cartilage tumors of bone by more objective methods, we examined the differentiation and proliferative activity of tumor cells in six enchondromas, five chondroblastomas, and 13 chondrosarcomas immunohistochemically. A variable number of cells in all tumors showed S-100 protein and vimentin immunoreactivity. In fully differentiated cartilage of enchondromas and low grade chondrosarcomas, tenascin, which is an extracellular matrix glycoprotein, was present in small amounts or absent but was increased at the periphery of tumor lobules and even in the matrix throughout the high grade chondrosarcomas. Higher rate and intensity of proliferating cell nuclear antigen (PCNA) reactivity were found in chondrosarcomas, especially in spindle-shaped cells of high grade tumors, than in enchondromas. The distribution of PCNA-positive cells almost corresponded to the regions with tenascin reactivity. One tumor of high grade chondrosarcoma showed p53 protein immunoreactivity. Aberrant expression of cytokeratin was observed in four chondroblastomas. The expression of desmin was identified in relatively large proportions of enchondromas and chondrosarcomas, regardless of their benign or malignant nature and histological grade. Smooth muscle or muscle-specific actins also were present in a smaller number of tumors. Based on these findings, it is concluded that unusual staining characteristics were present, in addition to those of a chondroblastic nature, in the cartilage tumors of bone. Tenascin and PCNA positivity of various degrees in all chondroblastomas may suggest that they are chondrogenic tumors having a relatively high proliferative activity, albeit their benign clinical course. Proliferative activity of tumor cells in enchondromas and chondrosarcomas correlated well with their histological grade. Tenascin may play a role in promoting tumor cell proliferation of cartilagenous neoplasms and, on the other hand, the alterations of extracellular matrix involving tenascin synthesis seem to be a result of tumor development.
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
January 1988,
Journal of cancer research and clinical oncology,
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
October 1958,
Pennsylvania medical journal (1928),
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
January 1987,
Instructional course lectures,
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
June 2002,
Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
December 1998,
Surgery,
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
July 2001,
Radiologic clinics of North America,
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
August 2004,
Hand clinics,
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
July 1993,
Radiologic clinics of North America,
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
December 1969,
Beitrage zur Orthopadie und Traumatologie,
T Hasegawa, and
K Seki, and
P Yang, and
T Hirose, and
K Hizawa, and
T Wada, and
J Wakabayashi
May 1949,
Annals of surgery,
